1. Home
  2. PESI vs CLLS Comparison

PESI vs CLLS Comparison

Compare PESI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perma-Fix Environmental Services Inc.

PESI

Perma-Fix Environmental Services Inc.

HOLD

Current Price

$18.96

Market Cap

367.9M

Sector

Industrials

ML Signal

HOLD

Logo Cellectis S.A.

CLLS

Cellectis S.A.

HOLD

Current Price

$3.16

Market Cap

394.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PESI
CLLS
Founded
1990
1999
Country
United States
France
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
367.9M
394.4M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
PESI
CLLS
Price
$18.96
$3.16
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.33
AVG Volume (30 Days)
419.7K
14.1K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
43.61
N/A
EPS
N/A
N/A
Revenue
$642,000.00
N/A
Revenue This Year
$34.62
N/A
Revenue Next Year
$77.02
$0.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.14
$2.35
52 Week High
$21.32
$5.48

Technical Indicators

Market Signals
Indicator
PESI
CLLS
Relative Strength Index (RSI) 60.06 49.62
Support Level $14.18 $2.94
Resistance Level $19.49 $3.47
Average True Range (ATR) 0.91 0.18
MACD -0.01 -0.02
Stochastic Oscillator 84.72 14.00

Price Performance

Historical Comparison
PESI
CLLS

About PESI Perma-Fix Environmental Services Inc.

Perma-Fix Environmental Services Inc is a nuclear services company and provider of nuclear and mixed waste management services. The company's nuclear waste services include treatment and management of radioactive and mixed waste (waste containing both hazardous and low-level radioactive waste). The company operates through two segments: i) The treatment segment: It offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and ii) the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Share on Social Networks: